BMI < 25 kg/m2 (n = 416) | ||||||
 Type 2 diabetes cases (n = 28) | ||||||
  Continuous Adipokines | Model 1* | Model 2†| ||||
HR | 95% CI | P | HR | 95% CI | P | |
   Log Plasma leptin (ng/mL) | 1.42 | (0.65, 3.10) | 0.38 | 1.14 | (0.50, 2.60) | 0.75 |
   Log Plasma adiponectin (ng/mL) | 1.01 | (0.49, 2.10) | 0.98 | 1.10 | (0.52, 2.33) | 0.80 |
BMI ≥ 25 - < 30 kg/m2 (n = 929) | ||||||
 Type 2 diabetes cases (n = 119) | ||||||
  Continuous Adipokines | Model 1* | Model 2†| ||||
HR | 95% CI | P | HR | 95% CI | P | |
   Log Plasma leptin (ng/mL) | 1.33 | (0.89, 2.01) | 0.17 | 1.00 | (0.65, 1.53) | 0.99 |
   Log Plasma adiponectin (ng/mL) | 0.63 | (0.46, 0.87) | <.01 | 0.77 | (0.55, 1.08) | 0.13 |
BMI ≥ 30 kg/m2 (n = 1311) | ||||||
 Type 2 diabetes cases (n = 308) | ||||||
  Continuous Adipokines | Model 1* | Model 2†| ||||
HR | 95% CI | p | HR | 95% CI | P | |
   Log Plasma leptin (ng/mL) | 1.09 | (0.83, 1.42) | 0.55 | 0.88 | (0.66, 1.16) | 0.37 |
   Log Plasma adiponectin (ng/mL) | 0.54 | (0.44, 0.66) | <.0001 | 0.69 | (0.56, 0.86) | <.001 |